Results 31 to 40 of about 16,189 (104)

Vaccine response in people with multiple sclerosis treated with fumarates

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the immune system, there may be concerns about vaccine efficacy and safety. Therefore, it is important
Matthew A. Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, Ivan Bozin, Seth Levin, Anne Gocke, Peter Wipfler   +6 more
doaj   +1 more source

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study [PDF]

Advances in Therapy, 2019
Catherine Taylor
exaly   +2 more sources

Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. [PDF]

Adv Ther
INTRODUCTION: Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are orally administered fumarate disease-modifying therapies (DMTs) for multiple sclerosis (MS).
Bowen JD, Stulc J, Hunter SF, Chen H, Lewin JB, Scaramozza M, Bozin I, Then Bergh F.   +7 more
europepmc   +2 more sources

Fumarate-triggered current consumption in CymAMtr-E. coli requires E. coli fumarate reductases.

, 2021
(A) Current consumption by the CymAMtr-E. coli in the wt (black) and ΔfrdABCD (orange) background upon addition of fumarate, showing reduced current consumption in the ΔfrdABCD background. (B) Current consumption by CymAMtr-E.
Moshe Baruch (257420), Sara Tejedor-Sanz (4912660), Caroline M. Ajo-Franklin (1351161), Lin Su (548272)   +3 more
core   +1 more source

sj-pdf-2-msj-10.1177_13524585231205708 – Supplemental material for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2023
Supplemental material, sj-pdf-2-msj-10.1177_13524585231205708 for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Barry A Singer, Douglas L Arnold, Jelena
Mark S Freedman (5235176), Ting Wang (16292), Tjalf Ziemssen (352981), Barry A Singer (7699400), Matthew Scaramozza (17311772), Sai L Shankar (17311775), Sibyl Wray (4656925), Miguel Angel Hernandez Perez (17311766), Hailu Chen (7820795), Jelena Drulovic (423245), Krzysztof Selmaj (3486809), Annette Wundes (5444552), Seth Levin (17311769), Wanda Castro-Borrero (5339651), Mark Gudesblatt (7533740), Ralf Gold (42956), Donald Negroski (12013663), Douglas L Arnold (5321081), Christopher C LaGanke (6386588), Robert T Naismith (5510369), Elzbieta Jasinska (8255024), Jiwon Oh (8349804), Florian Then Bergh (20098)   +22 more
core   +1 more source

sj-docx-1-msj-10.1177_13524585231205708 – Supplemental material for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2023
Supplemental material, sj-docx-1-msj-10.1177_13524585231205708 for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Barry A Singer, Douglas L Arnold ...
Mark S Freedman (5235176), Ting Wang (16292), Tjalf Ziemssen (352981), Barry A Singer (7699400), Matthew Scaramozza (17311772), Sai L Shankar (17311775), Sibyl Wray (4656925), Miguel Angel Hernandez Perez (17311766), Hailu Chen (7820795), Jelena Drulovic (423245), Krzysztof Selmaj (3486809), Annette Wundes (5444552), Seth Levin (17311769), Wanda Castro-Borrero (5339651), Mark Gudesblatt (7533740), Ralf Gold (42956), Donald Negroski (12013663), Douglas L Arnold (5321081), Christopher C LaGanke (6386588), Robert T Naismith (5510369), Elzbieta Jasinska (8255024), Jiwon Oh (8349804), Florian Then Bergh (20098)   +22 more
core   +1 more source

Rapid Hyperpolarization and Purification of the Metabolite Fumarate in Aqueous Solution [PDF]

, 2020
Hyperpolarized fumarate is a promising agent for carbon-13 magnetic resonance metabolic imaging of cellular necrosis. Molecular imaging applications require nuclear hyperpolarization to attain sufficient signal strength.
Kerstin, Münnemann, Francesca, Reineri, Gerd, Buntkowsky, John W., Blanchard, Silvio, Aime, Danila, Barskiy, Eleonora, Cavallari, Stephan, Knecht, Peter, Blümler, Dmitry, Budker, Erik, van Dyke, James, Eills, Malcolm H., Levitt, Laurynas, Dagys, Maksim, Tsukanov, Bea, Bliemel, Alexander, Pines   +16 more
core   +2 more sources

MSJ881761_supplementary_appendix – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2019
Supplemental material, MSJ881761_supplementary_appendix for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S Wolinsky ...
Mark S Freedman (5235176), Tjalf Ziemssen (352981), Ilda Bidollari (7820783), Jerry S Wolinsky (5965976), David Rezendes (7820792), Shifang Liu (2528113), Narinder Nangia (7820789), Jerome Hanna (7038269), Hailu Chen (7820795), Annette Wundes (5444552), Catherine Miller (202801), Mark Gudesblatt (7533740), Christopher LaGanke (7820774), Douglas L Arnold (5321081), Boris Kandinov (7820780), Dragana Obradovic (7820777), Maria Lopez-Bresnahan (7820786), Lili Yang (116313), Robert T Naismith (5510369), Richard Leigh-Pemberton (7313541)   +19 more
core   +1 more source

Ventricular‐vascular coupling at rest and immediately following maximal exercise in adults with and without multiple sclerosis

Physiological Reports, Volume 14, Issue 15, August 2026.
Abstract Multiple sclerosis (MS) may impair ventricular‐vascular coupling (VVC), a measure of the interaction between the cardiac and vascular systems. We evaluated if VVC differed between individuals with and without MS with similar age‐predicted fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

Persisting lymphopenia and dimethyl fumarate: A clinical commentary. [PDF]

, 2021
Severe prolonged lymphopenia as rare side-effect of dimethyl fumarate is mostly reversible. Caldito et al. report a case of persistent severe lymphopenia over 5 years after discontinuation of dimethyl fumarate.
Chan, Andrew, Diem, Lara
core   +1 more source